Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC study

Hiroshi Yatsuya, Hideaki Toyoshima, Koji Tamakoshi, Akiko Tamakoshi, Takaaki Kondo, Norihiko Hayakawa, Kiyomi Sakata, Shogo Kikuchi, Yoshiharu Hoshiyama, Yoshihisa Fujino, Tetsuya Mizoue, Noritaka Tokui, Takesumi Yoshimura, Mitsuru Mori, Yutaka Motohashi, Ichiro Tsuji, Yosikazu Nakamura, Hiroyasu Iso, Haruo Mikami, Yutaka InabaHiroshi Suzuki, Hiroyuki Shimizu, Kenji Wakai, Shinkan Tokudome, Yoshinori Ito, Shuji Hashimoto, Akio Koizumi, Takashi Kawamura, Yoshiyuki Watanabe, Tsuneharu Miki, Chigusa Date, Takayuki Nose, Akira Shibata, Naoyuki Okamoto, Hideo Shio, Yoshiyuki Ohno, Tomoyuki Kitagawa, Toshio Kuroki, Kazuo Tajima

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The prognosis of stomach cancer with advanced stage remains poor. New biomarkers of the disease that may contribute to establish the potential screening strategy would be of value for the early detection of individuals at high risk of the disease. Methods: We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the Japan Collaborative Cohort (JACC) Study, to evaluate serum levels of insulin-like growth factor I, II, and binding protein 3 (IFG-I, IGF-II, and IGFBP-3), transforming growth factor β-1 (TGF β 1), soluble fas (sFas) and superoxide dismutase activity (SOD) in 210 stomach cancer cases diagnosed in the JACC Study in relation to those levels in their 410 controls. Results: Among 6 serum biomarkers tested for case-control differences, only sFas level in female stomach cancer cases was significantly higher than that of controls (2.22 pg/ml vs. 2.04 pg/mL, respectively; P = 0.013 by two-way analysis of covariance controlling for matching variable). Conclusion: None of the biomarkers consistently predicted future risk of stomach cancer in both men and women in the present analysis. Serum sFas level in women, however, should be studied much more thoroughly whether it provides meaningful refinement of risk stratification, or it elucidate the mechanisms of tumorigenesis in women.

Original languageEnglish
JournalJournal of epidemiology
Volume15
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 14-10-2005

Fingerprint

Insulin-Like Growth Factor II
Fas Ligand Protein
Transforming Growth Factors
Insulin-Like Growth Factor I
Superoxide Dismutase
Stomach Neoplasms
Carrier Proteins
Japan
Cohort Studies
Biomarkers
Serum
Insulin-Like Growth Factor Binding Protein 3
Carcinogenesis

All Science Journal Classification (ASJC) codes

  • Epidemiology

Cite this

Yatsuya, Hiroshi ; Toyoshima, Hideaki ; Tamakoshi, Koji ; Tamakoshi, Akiko ; Kondo, Takaaki ; Hayakawa, Norihiko ; Sakata, Kiyomi ; Kikuchi, Shogo ; Hoshiyama, Yoshiharu ; Fujino, Yoshihisa ; Mizoue, Tetsuya ; Tokui, Noritaka ; Yoshimura, Takesumi ; Mori, Mitsuru ; Motohashi, Yutaka ; Tsuji, Ichiro ; Nakamura, Yosikazu ; Iso, Hiroyasu ; Mikami, Haruo ; Inaba, Yutaka ; Suzuki, Hiroshi ; Shimizu, Hiroyuki ; Wakai, Kenji ; Tokudome, Shinkan ; Ito, Yoshinori ; Hashimoto, Shuji ; Koizumi, Akio ; Kawamura, Takashi ; Watanabe, Yoshiyuki ; Miki, Tsuneharu ; Date, Chigusa ; Nose, Takayuki ; Shibata, Akira ; Okamoto, Naoyuki ; Shio, Hideo ; Ohno, Yoshiyuki ; Kitagawa, Tomoyuki ; Kuroki, Toshio ; Tajima, Kazuo. / Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC study. In: Journal of epidemiology. 2005 ; Vol. 15, No. SUPPL. 2.
@article{f76470e525b14d3bbad8921d3c67906b,
title = "Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC study",
abstract = "Background: The prognosis of stomach cancer with advanced stage remains poor. New biomarkers of the disease that may contribute to establish the potential screening strategy would be of value for the early detection of individuals at high risk of the disease. Methods: We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the Japan Collaborative Cohort (JACC) Study, to evaluate serum levels of insulin-like growth factor I, II, and binding protein 3 (IFG-I, IGF-II, and IGFBP-3), transforming growth factor β-1 (TGF β 1), soluble fas (sFas) and superoxide dismutase activity (SOD) in 210 stomach cancer cases diagnosed in the JACC Study in relation to those levels in their 410 controls. Results: Among 6 serum biomarkers tested for case-control differences, only sFas level in female stomach cancer cases was significantly higher than that of controls (2.22 pg/ml vs. 2.04 pg/mL, respectively; P = 0.013 by two-way analysis of covariance controlling for matching variable). Conclusion: None of the biomarkers consistently predicted future risk of stomach cancer in both men and women in the present analysis. Serum sFas level in women, however, should be studied much more thoroughly whether it provides meaningful refinement of risk stratification, or it elucidate the mechanisms of tumorigenesis in women.",
author = "Hiroshi Yatsuya and Hideaki Toyoshima and Koji Tamakoshi and Akiko Tamakoshi and Takaaki Kondo and Norihiko Hayakawa and Kiyomi Sakata and Shogo Kikuchi and Yoshiharu Hoshiyama and Yoshihisa Fujino and Tetsuya Mizoue and Noritaka Tokui and Takesumi Yoshimura and Mitsuru Mori and Yutaka Motohashi and Ichiro Tsuji and Yosikazu Nakamura and Hiroyasu Iso and Haruo Mikami and Yutaka Inaba and Hiroshi Suzuki and Hiroyuki Shimizu and Kenji Wakai and Shinkan Tokudome and Yoshinori Ito and Shuji Hashimoto and Akio Koizumi and Takashi Kawamura and Yoshiyuki Watanabe and Tsuneharu Miki and Chigusa Date and Takayuki Nose and Akira Shibata and Naoyuki Okamoto and Hideo Shio and Yoshiyuki Ohno and Tomoyuki Kitagawa and Toshio Kuroki and Kazuo Tajima",
year = "2005",
month = "10",
day = "14",
doi = "10.2188/jea.15.S120",
language = "English",
volume = "15",
journal = "Journal of Epidemiology",
issn = "0917-5040",
publisher = "Japan Epidemiology Association",
number = "SUPPL. 2",

}

Yatsuya, H, Toyoshima, H, Tamakoshi, K, Tamakoshi, A, Kondo, T, Hayakawa, N, Sakata, K, Kikuchi, S, Hoshiyama, Y, Fujino, Y, Mizoue, T, Tokui, N, Yoshimura, T, Mori, M, Motohashi, Y, Tsuji, I, Nakamura, Y, Iso, H, Mikami, H, Inaba, Y, Suzuki, H, Shimizu, H, Wakai, K, Tokudome, S, Ito, Y, Hashimoto, S, Koizumi, A, Kawamura, T, Watanabe, Y, Miki, T, Date, C, Nose, T, Shibata, A, Okamoto, N, Shio, H, Ohno, Y, Kitagawa, T, Kuroki, T & Tajima, K 2005, 'Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC study', Journal of epidemiology, vol. 15, no. SUPPL. 2. https://doi.org/10.2188/jea.15.S120

Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC study. / Yatsuya, Hiroshi; Toyoshima, Hideaki; Tamakoshi, Koji; Tamakoshi, Akiko; Kondo, Takaaki; Hayakawa, Norihiko; Sakata, Kiyomi; Kikuchi, Shogo; Hoshiyama, Yoshiharu; Fujino, Yoshihisa; Mizoue, Tetsuya; Tokui, Noritaka; Yoshimura, Takesumi; Mori, Mitsuru; Motohashi, Yutaka; Tsuji, Ichiro; Nakamura, Yosikazu; Iso, Hiroyasu; Mikami, Haruo; Inaba, Yutaka; Suzuki, Hiroshi; Shimizu, Hiroyuki; Wakai, Kenji; Tokudome, Shinkan; Ito, Yoshinori; Hashimoto, Shuji; Koizumi, Akio; Kawamura, Takashi; Watanabe, Yoshiyuki; Miki, Tsuneharu; Date, Chigusa; Nose, Takayuki; Shibata, Akira; Okamoto, Naoyuki; Shio, Hideo; Ohno, Yoshiyuki; Kitagawa, Tomoyuki; Kuroki, Toshio; Tajima, Kazuo.

In: Journal of epidemiology, Vol. 15, No. SUPPL. 2, 14.10.2005.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC study

AU - Yatsuya, Hiroshi

AU - Toyoshima, Hideaki

AU - Tamakoshi, Koji

AU - Tamakoshi, Akiko

AU - Kondo, Takaaki

AU - Hayakawa, Norihiko

AU - Sakata, Kiyomi

AU - Kikuchi, Shogo

AU - Hoshiyama, Yoshiharu

AU - Fujino, Yoshihisa

AU - Mizoue, Tetsuya

AU - Tokui, Noritaka

AU - Yoshimura, Takesumi

AU - Mori, Mitsuru

AU - Motohashi, Yutaka

AU - Tsuji, Ichiro

AU - Nakamura, Yosikazu

AU - Iso, Hiroyasu

AU - Mikami, Haruo

AU - Inaba, Yutaka

AU - Suzuki, Hiroshi

AU - Shimizu, Hiroyuki

AU - Wakai, Kenji

AU - Tokudome, Shinkan

AU - Ito, Yoshinori

AU - Hashimoto, Shuji

AU - Koizumi, Akio

AU - Kawamura, Takashi

AU - Watanabe, Yoshiyuki

AU - Miki, Tsuneharu

AU - Date, Chigusa

AU - Nose, Takayuki

AU - Shibata, Akira

AU - Okamoto, Naoyuki

AU - Shio, Hideo

AU - Ohno, Yoshiyuki

AU - Kitagawa, Tomoyuki

AU - Kuroki, Toshio

AU - Tajima, Kazuo

PY - 2005/10/14

Y1 - 2005/10/14

N2 - Background: The prognosis of stomach cancer with advanced stage remains poor. New biomarkers of the disease that may contribute to establish the potential screening strategy would be of value for the early detection of individuals at high risk of the disease. Methods: We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the Japan Collaborative Cohort (JACC) Study, to evaluate serum levels of insulin-like growth factor I, II, and binding protein 3 (IFG-I, IGF-II, and IGFBP-3), transforming growth factor β-1 (TGF β 1), soluble fas (sFas) and superoxide dismutase activity (SOD) in 210 stomach cancer cases diagnosed in the JACC Study in relation to those levels in their 410 controls. Results: Among 6 serum biomarkers tested for case-control differences, only sFas level in female stomach cancer cases was significantly higher than that of controls (2.22 pg/ml vs. 2.04 pg/mL, respectively; P = 0.013 by two-way analysis of covariance controlling for matching variable). Conclusion: None of the biomarkers consistently predicted future risk of stomach cancer in both men and women in the present analysis. Serum sFas level in women, however, should be studied much more thoroughly whether it provides meaningful refinement of risk stratification, or it elucidate the mechanisms of tumorigenesis in women.

AB - Background: The prognosis of stomach cancer with advanced stage remains poor. New biomarkers of the disease that may contribute to establish the potential screening strategy would be of value for the early detection of individuals at high risk of the disease. Methods: We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the Japan Collaborative Cohort (JACC) Study, to evaluate serum levels of insulin-like growth factor I, II, and binding protein 3 (IFG-I, IGF-II, and IGFBP-3), transforming growth factor β-1 (TGF β 1), soluble fas (sFas) and superoxide dismutase activity (SOD) in 210 stomach cancer cases diagnosed in the JACC Study in relation to those levels in their 410 controls. Results: Among 6 serum biomarkers tested for case-control differences, only sFas level in female stomach cancer cases was significantly higher than that of controls (2.22 pg/ml vs. 2.04 pg/mL, respectively; P = 0.013 by two-way analysis of covariance controlling for matching variable). Conclusion: None of the biomarkers consistently predicted future risk of stomach cancer in both men and women in the present analysis. Serum sFas level in women, however, should be studied much more thoroughly whether it provides meaningful refinement of risk stratification, or it elucidate the mechanisms of tumorigenesis in women.

UR - http://www.scopus.com/inward/record.url?scp=26244436238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244436238&partnerID=8YFLogxK

U2 - 10.2188/jea.15.S120

DO - 10.2188/jea.15.S120

M3 - Article

C2 - 16127223

AN - SCOPUS:26244436238

VL - 15

JO - Journal of Epidemiology

JF - Journal of Epidemiology

SN - 0917-5040

IS - SUPPL. 2

ER -